JASPER THERAPEUTICS, INC. (JSPR) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-60.33M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | -1.37× | Operating cash flow / net income. Period ending 2026-06-30. $-60.33M ÷ $44.03M ≈ -1.37× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -60.33M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 44.03M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-60.33M | (m) | (m) | (m) | (m) | $44.03M | (m) | (m) | (m) | -1.37× |
| 2026-03-31 | (m) | (m) | $-68.87M | (m) | (m) | (m) | (m) | $-55.73M | (m) | (m) | (m) | 1.24× |
| 2025-12-31 | (m) | (m) | $-77.16M | (m) | (m) | (m) | (m) | $-75.80M | (m) | (m) | (m) | 1.02× |
| 2025-09-30 | (m) | (m) | $-76.43M | (m) | (m) | (m) | (m) | $-91.02M | (m) | (m) | (m) | 0.84× |
| 2025-06-30 | (m) | (m) | $-73.48M | (m) | (m) | (m) | (m) | $-90.92M | (m) | (m) | (m) | 0.81× |
| 2025-03-31 | (m) | (m) | $-69.71M | (m) | (m) | (m) | (m) | $-78.78M | (m) | (m) | (m) | 0.88× |
| 2024-12-31 | (m) | (m) | $-62.60M | (m) | (m) | (m) | (m) | $-71.27M | (m) | (m) | (m) | 0.88× |
| 2024-09-30 | (m) | (m) | $-57.95M | (m) | (m) | (m) | (m) | $-63.53M | (m) | (m) | (m) | 0.91× |
| 2024-06-30 | (m) | (m) | $-55.88M | (m) | (m) | (m) | (m) | $-62.44M | (m) | (m) | (m) | 0.89× |
| 2024-03-31 | (m) | (m) | $-57.47M | (m) | (m) | (m) | (m) | $-63.93M | (m) | (m) | (m) | 0.90× |
| 2023-12-31 | (m) | (m) | $-52.07M | (m) | (m) | (m) | (m) | $-64.47M | (m) | (m) | (m) | 0.81× |
| 2023-09-30 | (m) | (m) | $-48.23M | (m) | (m) | (m) | (m) | $-61.09M | (m) | (m) | (m) | 0.79× |
| 2023-06-30 | (m) | (m) | $-45.90M | (m) | (m) | (m) | (m) | $-55.41M | (m) | (m) | (m) | 0.83× |
| 2023-03-31 | (m) | (m) | $-41.98M | (m) | (m) | (m) | (m) | $-49.74M | (m) | (m) | (m) | 0.84× |
| 2022-12-31 | (m) | (m) | $-45.86M | (m) | (m) | (m) | (m) | $-37.69M | (m) | (m) | (m) | 1.22× |
| 2022-09-30 | (m) | (m) | $-47.80M | (m) | (m) | (m) | (m) | $-33.53M | (m) | (m) | (m) | 1.43× |
| 2022-06-30 | (m) | (m) | $-45.26M | (m) | (m) | (m) | (m) | $-25.08M | (m) | (m) | (m) | 1.80× |
| 2022-03-31 | (m) | (m) | $-41.70M | (m) | (m) | (m) | (m) | $-23.09M | (m) | (m) | (m) | 1.81× |
| 2021-12-31 | (m) | (m) | $-33.68M | (m) | (m) | (m) | (m) | $-30.64M | (m) | (m) | (m) | 1.10× |
| 2021-09-30 | (m) | (m) | $-6.86M | (m) | (m) | (m) | (m) | $-6.58M | (m) | (m) | (m) | 1.04× |
| 2021-06-30 | (m) | (m) | $-912.89K | (m) | (m) | (m) | (m) | $-2.55M | (m) | (m) | (m) | 0.36× |
| 2021-03-31 | (m) | (m) | $-725.86K | (m) | (m) | (m) | (m) | $-2.41M | (m) | (m) | (m) | 0.30× |
| 2020-12-31 | (m) | (m) | $-640.98K | (m) | (m) | (m) | (m) | $-590.70K | (m) | (m) | (m) | 1.09× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |